| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TGF beta 1 |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma.[1] It was dropped from further development in favour of fresolimumab,[2] which was being developed by Genzyme as of 2006.[3]
- ^ Sorbera LA (2004). "Metelimumab: Agent for scleroderma prop inn human anti-TGF-β1 monoclonal antibody". Drugs of the Future. 29 (11): 1081–3. doi:10.1358/dof.2004.029.11.860002.
- ^ Foley S (10 February 2004). "CAT may abandon skin drug after trial results disappoint".
{{cite journal}}: Cite journal requires|journal=(help) - ^ "Tasidotin". Genzyme. 2006. Archived from the original on 2006-09-02. Retrieved 2009-07-27.